Omeros (OMER) Projected to Post Quarterly Earnings on Tuesday

Omeros (NASDAQ:OMER) will likely be posting its Q4 2025 results after the market closes on Tuesday, March 31st. Analysts expect Omeros to post earnings of ($0.55) per share and revenue of $40.1490 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Omeros Price Performance

Shares of NASDAQ OMER opened at $9.88 on Monday. The business has a 50-day moving average price of $11.48 and a 200 day moving average price of $9.67. The stock has a market cap of $700.49 million, a PE ratio of -4.89 and a beta of 2.45. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65.

Wall Street Analyst Weigh In

OMER has been the subject of a number of research reports. HC Wainwright boosted their price objective on Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. D. Boral Capital restated a “buy” rating and set a $36.00 target price on shares of Omeros in a research report on Tuesday, January 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $40.33.

Insider Transactions at Omeros

In other Omeros news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total transaction of $369,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 12.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its holdings in shares of Omeros by 1,201.1% in the third quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock valued at $1,706,000 after purchasing an additional 384,168 shares during the period. State Street Corp raised its stake in shares of Omeros by 26.9% during the fourth quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after purchasing an additional 333,798 shares during the last quarter. Two Sigma Investments LP lifted its holdings in shares of Omeros by 39.3% during the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after purchasing an additional 263,095 shares during the period. Jump Financial LLC acquired a new stake in shares of Omeros during the fourth quarter worth $3,916,000. Finally, Informed Momentum Co LLC purchased a new position in Omeros in the 4th quarter valued at $3,563,000. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.